Related Experiment Video

Updated: Sep 24, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K

YES, a novel therapeutic target in hepatocellular carcinoma

Marjorie Lapouge1, Sylvain Meloche1,2,3

  • 1Signaling and Cell Growth Laboratory, Institute for Research in Immunology and Cancer, Montreal, Quebec, Canada.

Molecular & Cellular Oncology
|May 9, 2022
PubMed

Insights

Targeting the novel YES-YAP/TAZ signaling axis offers a new strategy for advanced liver cancer. This study highlights tyrosine kinase YES as a potential therapeutic target for hepatocellular carcinoma (HCC) treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Targeted therapies for advanced hepatocellular carcinoma (HCC) require identification of actionable oncogenic pathways.
  • The Hippo signaling pathway, involving YAP/TAZ, is crucial in liver cancer development.
  • Novel signaling axes in HCC remain to be fully elucidated.

Purpose of the Study:

  • To identify key signaling pathways driving advanced-stage HCC.
  • To investigate the role of the novel YES-YAP/TAZ signaling axis in liver cancer.
  • To evaluate tyrosine kinase YES as a potential therapeutic target in HCC.

Main Methods:

  • Analysis of oncogenic signaling pathways in HCC.
  • Investigation of the YES-YAP/TAZ signaling axis.
  • Assessment of tyrosine kinase YES as a therapeutic target.

Main Results:

  • A novel YES-YAP/TAZ signaling axis was identified in liver cancer development.
  • The tyrosine kinase YES was confirmed to be involved in HCC progression.
  • YES emerges as a promising therapeutic target for HCC.

Conclusions:

  • The YES-YAP/TAZ axis represents a critical signaling pathway in advanced HCC.
  • Targeting tyrosine kinase YES could lead to effective new treatments for liver cancer.
  • Further research into this axis may uncover new therapeutic strategies for HCC.
Keywords:
SRC-family kinasesYAP/TAZYEShepatocellular carcinomakinase inhibitors

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.4K
Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids07:25

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids

Published on: August 18, 2023

2.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K